Geode Capital Management LLC raised its stake in Twist Bioscience Corp (NASDAQ:TWST) by 27.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 404,804 shares of the company’s stock after buying an additional 86,457 shares during the period. Geode Capital Management LLC owned approximately 1.14% of Twist Bioscience worth $12,378,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in TWST. Wellington Management Group LLP acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $40,616,000. Legal & General Group Plc lifted its stake in Twist Bioscience by 14.7% during the first quarter. Legal & General Group Plc now owns 5,311 shares of the company’s stock valued at $163,000 after buying an additional 679 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Twist Bioscience by 7.9% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 521,810 shares of the company’s stock valued at $15,957,000 after acquiring an additional 38,268 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Twist Bioscience by 3.9% in the 1st quarter. Alliancebernstein L.P. now owns 26,700 shares of the company’s stock worth $816,000 after purchasing an additional 1,000 shares during the period. Finally, Nuveen Asset Management LLC grew its position in Twist Bioscience by 212.2% during the 1st quarter. Nuveen Asset Management LLC now owns 266,178 shares of the company’s stock worth $8,140,000 after purchasing an additional 180,909 shares in the last quarter. Institutional investors own 75.31% of the company’s stock.
In related news, CEO Emily M. Leproust sold 14,513 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $39.27, for a total value of $569,925.51. Following the completion of the sale, the chief executive officer now directly owns 774,751 shares in the company, valued at $30,424,471.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Banyai sold 22,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $39.66, for a total transaction of $872,520.00. Following the transaction, the insider now directly owns 592,051 shares in the company, valued at $23,480,742.66. The disclosure for this sale can be found here. In the last three months, insiders sold 164,586 shares of company stock valued at $6,456,404. 25.10% of the stock is currently owned by company insiders.
A number of research analysts have recently weighed in on TWST shares. BidaskClub downgraded Twist Bioscience from a “buy” rating to a “hold” rating in a report on Friday, June 5th. Zacks Investment Research cut Twist Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, ValuEngine raised shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $42.00.
Twist Bioscience stock opened at $45.30 on Wednesday. Twist Bioscience Corp has a 12 month low of $18.52 and a 12 month high of $45.63. The company has a quick ratio of 8.26, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.67 billion, a P/E ratio of -10.25 and a beta of 0.21. The company’s fifty day simple moving average is $39.09 and its 200-day simple moving average is $30.48.
Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.10). Twist Bioscience had a negative net margin of 222.66% and a negative return on equity of 71.31%. The firm had revenue of $19.30 million for the quarter, compared to analyst estimates of $17.18 million. During the same period in the previous year, the business posted ($0.93) EPS. Twist Bioscience’s revenue for the quarter was up 41.9% on a year-over-year basis. On average, equities research analysts expect that Twist Bioscience Corp will post -3 earnings per share for the current fiscal year.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corp (NASDAQ:TWST).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.